X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31535) 31535
Book Chapter (122) 122
Newsletter (43) 43
Magazine Article (42) 42
Newspaper Article (10) 10
Book / eBook (8) 8
Dissertation (4) 4
Book Review (3) 3
Conference Proceeding (3) 3
Publication (3) 3
Reference (3) 3
Transcript (2) 2
Government Document (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26700) 26700
male (14325) 14325
female (14261) 14261
middle aged (10369) 10369
adult (9430) 9430
recombinant proteins (8831) 8831
animals (7543) 7543
recombinant proteins - therapeutic use (7494) 7494
aged (6848) 6848
treatment outcome (5640) 5640
recombinant proteins - adverse effects (4706) 4706
recombinant proteins - administration & dosage (3783) 3783
oncology (3584) 3584
hematology (3243) 3243
mice (3128) 3128
interferon-alpha - therapeutic use (3027) 3027
interferon-alpha - adverse effects (3020) 3020
therapy (2986) 2986
immunology (2889) 2889
adolescent (2830) 2830
drug therapy, combination (2769) 2769
pharmacology & pharmacy (2504) 2504
care and treatment (2393) 2393
health aspects (2306) 2306
hepatitis c, chronic - drug therapy (2230) 2230
proteins (2162) 2162
time factors (2159) 2159
dose-response relationship, drug (2158) 2158
antiviral agents - therapeutic use (2151) 2151
cancer (2108) 2108
erythropoietin - therapeutic use (2086) 2086
research (2064) 2064
analysis (1978) 1978
interferon-alpha - administration & dosage (1949) 1949
recombinant proteins - pharmacology (1898) 1898
antiviral agents - adverse effects (1881) 1881
child (1856) 1856
drug administration schedule (1855) 1855
medicine, research & experimental (1821) 1821
expression (1743) 1743
gastroenterology & hepatology (1702) 1702
prospective studies (1691) 1691
risk factors (1675) 1675
retrospective studies (1656) 1656
polyethylene glycols - therapeutic use (1651) 1651
aged, 80 and over (1641) 1641
safety (1637) 1637
ribavirin - therapeutic use (1630) 1630
surgery (1628) 1628
interferon (1605) 1605
biotechnology & applied microbiology (1559) 1559
drug therapy (1506) 1506
recombinant fusion proteins - therapeutic use (1498) 1498
anemia (1486) 1486
medicine & public health (1486) 1486
chemotherapy (1448) 1448
transplantation (1447) 1447
recombinant proteins - metabolism (1424) 1424
young adult (1410) 1410
medicine, general & internal (1404) 1404
anemia - drug therapy (1388) 1388
rats (1378) 1378
double-blind method (1374) 1374
biochemistry & molecular biology (1371) 1371
follow-up studies (1352) 1352
efficacy (1348) 1348
erythropoietin (1321) 1321
antineoplastic combined chemotherapy protocols - therapeutic use (1311) 1311
hepatitis c (1304) 1304
double-blind (1290) 1290
recombinant-human-erythropoietin (1248) 1248
clinical trials (1241) 1241
polyethylene glycols - adverse effects (1234) 1234
immunotherapy (1226) 1226
recombinant proteins - genetics (1224) 1224
antineoplastic combined chemotherapy protocols - adverse effects (1216) 1216
ribavirin (1212) 1212
ribavirin - adverse effects (1201) 1201
erythropoietin - adverse effects (1196) 1196
antibodies (1184) 1184
antineoplastic agents - adverse effects (1155) 1155
clinical trials as topic (1135) 1135
abridged index medicus (1120) 1120
research article (1088) 1088
gene expression (1083) 1083
antiviral agents - administration & dosage (1074) 1074
urology & nephrology (1074) 1074
trial (1071) 1071
anemia - etiology (1065) 1065
filgrastim (1064) 1064
child, preschool (1059) 1059
endocrinology & metabolism (1056) 1056
cell biology (1046) 1046
management (1032) 1032
physiological aspects (1032) 1032
infection (1019) 1019
mortality (1019) 1019
granulocyte colony-stimulating factor - therapeutic use (1012) 1012
erythropoietin - administration & dosage (999) 999
disease models, animal (990) 990
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (30623) 30623
German (331) 331
Japanese (289) 289
French (231) 231
Spanish (213) 213
Chinese (167) 167
Russian (98) 98
Italian (71) 71
Portuguese (49) 49
Polish (48) 48
Czech (29) 29
Hungarian (28) 28
Dutch (21) 21
Serbian (18) 18
Danish (11) 11
Korean (10) 10
Norwegian (7) 7
Swedish (7) 7
Bulgarian (5) 5
Slovak (5) 5
Ukrainian (5) 5
Finnish (4) 4
Croatian (3) 3
Hebrew (3) 3
Turkish (3) 3
Romanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 2016, Volume 120, pp. 1 - 14
[Display omitted] Vaccines have been the single most significant advancement in public health, preventing morbidity and mortality in millions of people... 
Nanoparticles | Vaccine | SAPN | Adjuvant | Rationally designed | GOLD NANOPARTICLES | HEPATITIS-B-VACCINE | ESCHERICHIA-COLI | NANOPARTICLE VACCINES | MONOPHOSPHORYL-LIPID-A | TOLL-LIKE RECEPTOR-5 | T-CELL RESPONSES | IMMUNE-RESPONSES | VIRUS-LIKE PARTICLES | PHARMACOLOGY & PHARMACY | ANTIGEN-CONTAINING LIPOSOMES | Recombinant Proteins - therapeutic use | Veterinary Drugs - adverse effects | History, 21st Century | Nanoparticles - chemistry | Humans | Vaccines, Synthetic - immunology | Antigens - therapeutic use | Vaccines - chemistry | Allergy and Immunology - history | Nanoparticles - therapeutic use | Vaccines, Subunit - adverse effects | Biopharmaceutics - history | Adjuvants, Immunologic - therapeutic use | Communicable Diseases - veterinary | Chemistry, Pharmaceutical - trends | Vaccines, Synthetic - chemistry | History, 20th Century | Recombinant Proteins - chemistry | Veterinary Drugs - immunology | Protein Engineering - trends | Antigens - chemistry | Communicable Disease Control - trends | Biopharmaceutics - methods | Drug Delivery Systems - trends | Protein Engineering - veterinary | Drug Delivery Systems - adverse effects | Veterinary Drugs - chemistry | Veterinary Drugs - therapeutic use | Drug Delivery Systems - veterinary | Nanoparticles - adverse effects | Recombinant Proteins - adverse effects | Vaccines - therapeutic use | Adjuvants, Immunologic - adverse effects | Antigens - adverse effects | Vaccines, Subunit - therapeutic use | Vaccines, Synthetic - adverse effects | Adjuvants, Immunologic - chemistry | Allergy and Immunology - trends | Drug Design | Chemistry, Pharmaceutical - history | Communicable Disease Control - history | Vaccines, Subunit - chemistry | Biopharmaceutics - trends | Vaccines - immunology | Vaccines, Synthetic - therapeutic use | Vaccines, Subunit - immunology | Protein Folding | Vaccines - adverse effects | Animals | Recombinant Proteins - immunology | Communicable Diseases - immunology | Antigens - immunology | History, 19th Century | Vaccines | Rationally Designed
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
.... Heparin also binds to cells and plasma proteins other than antithrombin causing unpredictable pharmacokinetic and pharmacodynamic properties and triggering nonhemorrhagic side effects... 
RESPIRATORY SYSTEM | LOW-MOLECULAR-WEIGHT | ACUTE MYOCARDIAL-INFARCTION | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | RECOMBINANT FACTOR VIIA | PATHOLOGISTS CONFERENCE XXXI | PARTIAL THROMBOPLASTIN TIME | ANTI-FACTOR-XA | ACUTE VENOUS THROMBOEMBOLISM | UNFRACTIONATED HEPARIN | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Vaccine, ISSN 0264-410X, 2013, Volume 31, Issue 3, pp. 524 - 532
Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related... 
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | NEUTRALIZING ANTIBODIES | IMMUNE GLOBULIN | COTTON RATS | INFLUENZA | RISK | IMMUNOLOGY | F-GLYCOPROTEIN | INFANTS | INFECTION | YOUNG-CHILDREN | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Life Sciences
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 6, p. e0198184
Background Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and... 
AUTOIMMUNE THROMBOCYTOPENIA | TREATMENT OPTIONS | ADULT PATIENTS | INTRAVENOUS GAMMA-GLOBULIN | MANAGEMENT | ANTI-D | MEDICAL THERAPY | SAFETY | PURPURA | ROMIPLOSTIM | MULTIDISCIPLINARY SCIENCES | Prednisolone - adverse effects | Azathioprine - therapeutic use | Pyrazoles - therapeutic use | Benzoates - therapeutic use | Recombinant Fusion Proteins - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunoglobulins, Intravenous - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Male | Dapsone - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - drug therapy | Receptors, Fc - therapeutic use | Splenectomy | Young Adult | Aged, 80 and over | Child | Rituximab - adverse effects | Purpura, Thrombocytopenic, Idiopathic - surgery | Combined Modality Therapy | Remission Induction | Cyclosporine - therapeutic use | Dexamethasone - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Rho(D) Immune Globulin - adverse effects | Cyclosporine - adverse effects | Adolescent | Rho(D) Immune Globulin - therapeutic use | Dapsone - adverse effects | Benzoates - adverse effects | Recombinant Fusion Proteins - therapeutic use | Thrombopoietin - therapeutic use | Purpura, Thrombocytopenic, Idiopathic - therapy | Rituximab - therapeutic use | Adult | Female | Prednisolone - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Drug Resistance | Pyrazoles - adverse effects | Hydrazines - therapeutic use | Treatment Outcome | Thrombopoietin - adverse effects | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Hydrazines - adverse effects | Thrombocytopenic purpura | Clinical trials | Treatment outcome | Care and treatment | Analysis | Drugs | Thrombocytopenia | Therapy | Immunoglobulins | Dexamethasone | Intravenous administration | Medical treatment | Patients | Immunosuppressive agents | Bleeding | Medicine | Remission | Clinical medicine | Azathioprine | Drug dosages | Prednisolone
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 21, pp. 1572 - 1587
..., interleukin-2, ipilimumab, tremelimumab, thalidomide, and lenalidomide. Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid... 
TYROSINE KINASE INHIBITORS | DENILEUKIN DIFTITOX | PHASE-II TRIAL | ONCOLOGY | SUNITINIB INDUCES HYPOTHYROIDISM | ALPHA-INTERFERON THERAPY | RECOMBINANT INTERLEUKIN-2 | HIGH-DOSE INTERLEUKIN-2 | THYROXINE-BINDING GLOBULIN | RENAL-CELL CARCINOMA | CHRONIC VIRAL-HEPATITIS | Hypothyroidism - chemically induced | Thyroid Function Tests | Hyperthyroidism - diagnosis | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Tetrahydronaphthalenes - adverse effects | Hyperthyroidism - chemically induced | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Diphtheria Toxin - adverse effects | Thyroid Hormones - blood | Anticarcinogenic Agents - adverse effects | Interleukin-2 - analogs & derivatives | Thyroiditis, Autoimmune - chemically induced | Molecular Targeted Therapy - methods | Thyroid Gland - drug effects | Thalidomide - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Hyperthyroidism - blood | Radioimmunotherapy | Hypopituitarism - etiology | Hypothyroidism - diagnosis | Alemtuzumab | Hypothyroidism - etiology | Neoplasms - drug therapy | Iodine Radioisotopes - administration & dosage | Hypopituitarism - complications | Neoplasms - immunology | Hypothyroidism - drug therapy | Quality of Life | Interferon-alpha - adverse effects | Hypothyroidism - blood | Thyroid Gland - metabolism | Antibodies, Neoplasm - adverse effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Complications and side effects | Usage | Thyroid diseases | Diagnosis | Antineoplastic agents | Thyroid gland function tests | Risk factors | Index Medicus | Review
Journal Article